Stockreport

OS Therapies provides first half 2026 corporate outlook [Seeking Alpha]

OS Therapies Incorporated  (OSTX) 
PDF The outlook highlights planned submissions to seek regulatory approval for the its lead candidate OST-HER2 in the U.S., U.K. and Europe, the expected release of Phase 2 [Read more]